头孢哌酮/舒巴坦治疗慢性心衰并肺部感染的疗效
|
摘要
目的探讨慢性心衰并肺部感染患者给予头孢哌酮/舒巴坦治疗的疗效。方法随机选取2015年5月-2017年5月医院收治的慢性心衰并肺部感染患者60例,依据治疗方法分为头孢哌酮/舒巴坦组(n=30)和头孢曲松钠组(n=30)两组,对两组患者的临床疗效、菌株分离及完全清除情况、退热时间、咳嗽消失时间、喘息消失时间、肺部湿啰音消失时间、住院时间、不良反应发生情况进行统计分析。结果头孢哌酮/舒巴坦组患者治疗的总有效率96.67%(29/30)显著高于头孢曲松钠组73.33%(22/30)(P<0.05),退热时间、咳嗽消失时间、喘息消失时间、肺部湿啰音消失时间、住院时间均显著短于头孢曲松钠组(P<0.05),不良反应发生率3.33%(1/30)显著低于头孢曲松钠组16.67%(5/30)(P<0.05)。头孢哌酮/舒巴坦组分离菌株11株,完全清除10株,完全清除率为90.91%;头孢曲松钠组分离菌株10株,完全清除5株,完全清除率为50.00%。头孢哌酮/舒巴坦组的菌株完全清除率显著高于头孢曲松钠组(P<0.05)。结论慢性心衰并肺部感染患者给予头孢哌酮/舒巴坦治疗的疗效较头孢曲松钠显著。
OBJECTIVE To explore the efficacy of cefoperazone-sulbactam in treatment of chronic heart failure patients complicated with pulmonary infection.METHODS A total of 60 chronic heart failure patients complicated with pulmonary infection who were treated in the hospitlafrom May 2015 to May 201 were randomly enrolled in the study and divided into the cefoperazone-sulbactam group with 30 cases and the ceftriaxone sodium group with30 cases according to the treatment measures.The clinical curative effect,number of isolated strains,completed eradication rate,time of fever abatement,time of disappearance of cough,time of disappearance of wheezing,time of disappearance of pulmonary rales,length of hospital stay and incidence of adverse reactions were statistically analyzed.RESULTS The total effective rates of treatment of the cefoperazone-sulbactam group was 96.67%(29/30),significantly higher than 73.33%(22/30)of the ceftriaxone sodium group(P <0.05).The time of fever abatement,time of disappearance of cough,time of disappearance of wheezing,time of disappearance of pulmonary rales and length of hospital stay were sighificantly shorter in the cefoperazone-sulbactam group than in the ceftriaxone sodium group(P<0.05).The incidence of adverse reactions of the cefoperazone-sulbactam group was 3.33%(1/30),significantly lower than 16.67%(5/30)of the ceftriaxone sodium group(P<0.05).Totally 11 strains were isolated and 10 strains were completely eradicated,with the rate of complete eradication 90.91%;totally 10 strains were isolated and 5 strains were completely eradicated,with the rate of complete eradication50.00%;the rate of complete eradication of the cefoperazone-sulbactam group was significantly higher than that of the ceftriaxone sodium group(P<0.05).CONCLUSION Cefoperzone-sulbactam achieves more remarkable effect on treatment of the chronic heart failure patients complicated with pulmonary infection than ceftriaxone sodium does.
OBJECTIVE To explore the efficacy of cefoperazone-sulbactam in treatment of chronic heart failure patients complicated with pulmonary infection.METHODS A total of 60 chronic heart failure patients complicated with pulmonary infection who were treated in the hospitlafrom May 2015 to May 201 were randomly enrolled in the study and divided into the cefoperazone-sulbactam group with 30 cases and the ceftriaxone sodium group with30 cases according to the treatment measures.The clinical curative effect,number of isolated strains,completed eradication rate,time of fever abatement,time of disappearance of cough,time of disappearance of wheezing,time of disappearance of pulmonary rales,length of hospital stay and incidence of adverse reactions were statistically analyzed.RESULTS The total effective rates of treatment of the cefoperazone-sulbactam group was 96.67%(29/30),significantly higher than 73.33%(22/30)of the ceftriaxone sodium group(P <0.05).The time of fever abatement,time of disappearance of cough,time of disappearance of wheezing,time of disappearance of pulmonary rales and length of hospital stay were sighificantly shorter in the cefoperazone-sulbactam group than in the ceftriaxone sodium group(P<0.05).The incidence of adverse reactions of the cefoperazone-sulbactam group was 3.33%(1/30),significantly lower than 16.67%(5/30)of the ceftriaxone sodium group(P<0.05).Totally 11 strains were isolated and 10 strains were completely eradicated,with the rate of complete eradication 90.91%;totally 10 strains were isolated and 5 strains were completely eradicated,with the rate of complete eradication50.00%;the rate of complete eradication of the cefoperazone-sulbactam group was significantly higher than that of the ceftriaxone sodium group(P<0.05).CONCLUSION Cefoperzone-sulbactam achieves more remarkable effect on treatment of the chronic heart failure patients complicated with pulmonary infection than ceftriaxone sodium does.
引文
[1]赵伟锋.头孢曲松钠与青霉素钠对心力衰竭伴肺炎患者临床疗效的比较[J].抗感染药学,2017,14(6):1230-1232.
[2]Carvalho VO,Mezzani A.Aerobic exercise training intensity in patients with chronic heart failure:principles of assessment and prescription[J].Eur J Cardiovasc Prev Rehabil,2016,18(1):5-14.
[3]谢晓林,刘路平,孔菁,等.头孢哌酮/舒巴坦在心力衰竭患者肺部感染中的治疗效果与感染指标的控制观察[J].中华医院感染学杂志,2017,27(11):2424-2426.
[4]Nagappa M,Ho G,Patra J,et al.Postoperative outcomes in obstructive sleep apnea patients undergoing cardiac surgery:a systematic review and meta-analysis of comparative studies[J].Anesth Analg,2017,125(6):2030-2037.
[5]孙慧敏,郑轶,张凡,等.头孢哌酮联合舒巴坦治疗慢性心力衰竭患者肺部感染的临床分析[J].中华医院感染学杂志,2016,26(16):3693-3695.
[6]Al-Eyadhy AA,Hasan G,Bassrawi R,et al.Cytomegalovirus associated severe pneumonia,multi-organ failure and Ganciclovir associated arrhythmia in immunocompetent child[J].JInfect Chemother,2017,23(12):844-847.
[7]王冠超.头孢哌酮联合舒巴坦治疗慢性心力衰竭并肺部感染的效果观察[J].临床合理用药,2014,7(3A):49.
[8]Metersky ML,Eldridge N,Wang Y,et al.National trends in the frequency of bladder catheterization and physician-diagnosed catheter-associated urinary tract infections:results from the Medicare Patient Safety Monitoring System[J].Am J Infect Control,2017,45(8):901-904.
[9]林芳,冯旭霞,陈邢玉,等.慢性心力衰竭患者合并肺部感染的病原菌分布及耐药性分析[J].中华医院感染学杂志,2017,27(4):796-799.
[10]谢晓林,刘路平,孔菁,等.头孢哌酮/舒巴坦在心力衰竭患者肺部感染中的治疗效果与感染指标的控制观察[J].中华医院感染学杂志,2017,27(11):2424-2426.
[11]龙鼎,喻莉,杨军辉.替加环素联合头孢哌酮舒巴坦钠治疗广泛耐药鲍曼不动杆菌老年肺部感染疗效观察[J].中华实用诊断与治疗杂志,2016,30(5):512-514.
[12]Verma AA,Guo Y,Kwan JL,et al.Patient characteristics,resource use and outcomes associated with general internal medicine hospital care:the General Medicine Inpatient Initiative(GEMINI)retrospective cohort study[J].CMAJ Open,2017,5(4):E842-E849.
[13]李志芳,段成城,董丽妍,等.老年心力衰竭肺部感染患者舒巴坦应用的效果分析[J].中华医院感染学杂志,2016,26(8):1767-1769.
[14]Coventry LL,Pickles S,Sin M,et al.Impact of the Orthopaedic Nurse Practitioner role on acute hospital length of stay and cost-savings for patients with hip fracture:a retrospective cohort study[J].J Adv Nurs,2017,73(11):2652-2663.
[2]Carvalho VO,Mezzani A.Aerobic exercise training intensity in patients with chronic heart failure:principles of assessment and prescription[J].Eur J Cardiovasc Prev Rehabil,2016,18(1):5-14.
[3]谢晓林,刘路平,孔菁,等.头孢哌酮/舒巴坦在心力衰竭患者肺部感染中的治疗效果与感染指标的控制观察[J].中华医院感染学杂志,2017,27(11):2424-2426.
[4]Nagappa M,Ho G,Patra J,et al.Postoperative outcomes in obstructive sleep apnea patients undergoing cardiac surgery:a systematic review and meta-analysis of comparative studies[J].Anesth Analg,2017,125(6):2030-2037.
[5]孙慧敏,郑轶,张凡,等.头孢哌酮联合舒巴坦治疗慢性心力衰竭患者肺部感染的临床分析[J].中华医院感染学杂志,2016,26(16):3693-3695.
[6]Al-Eyadhy AA,Hasan G,Bassrawi R,et al.Cytomegalovirus associated severe pneumonia,multi-organ failure and Ganciclovir associated arrhythmia in immunocompetent child[J].JInfect Chemother,2017,23(12):844-847.
[7]王冠超.头孢哌酮联合舒巴坦治疗慢性心力衰竭并肺部感染的效果观察[J].临床合理用药,2014,7(3A):49.
[8]Metersky ML,Eldridge N,Wang Y,et al.National trends in the frequency of bladder catheterization and physician-diagnosed catheter-associated urinary tract infections:results from the Medicare Patient Safety Monitoring System[J].Am J Infect Control,2017,45(8):901-904.
[9]林芳,冯旭霞,陈邢玉,等.慢性心力衰竭患者合并肺部感染的病原菌分布及耐药性分析[J].中华医院感染学杂志,2017,27(4):796-799.
[10]谢晓林,刘路平,孔菁,等.头孢哌酮/舒巴坦在心力衰竭患者肺部感染中的治疗效果与感染指标的控制观察[J].中华医院感染学杂志,2017,27(11):2424-2426.
[11]龙鼎,喻莉,杨军辉.替加环素联合头孢哌酮舒巴坦钠治疗广泛耐药鲍曼不动杆菌老年肺部感染疗效观察[J].中华实用诊断与治疗杂志,2016,30(5):512-514.
[12]Verma AA,Guo Y,Kwan JL,et al.Patient characteristics,resource use and outcomes associated with general internal medicine hospital care:the General Medicine Inpatient Initiative(GEMINI)retrospective cohort study[J].CMAJ Open,2017,5(4):E842-E849.
[13]李志芳,段成城,董丽妍,等.老年心力衰竭肺部感染患者舒巴坦应用的效果分析[J].中华医院感染学杂志,2016,26(8):1767-1769.
[14]Coventry LL,Pickles S,Sin M,et al.Impact of the Orthopaedic Nurse Practitioner role on acute hospital length of stay and cost-savings for patients with hip fracture:a retrospective cohort study[J].J Adv Nurs,2017,73(11):2652-2663.